New Drug Development in Haematology
The development of antibiotic resistance in particular stems from the drugs targeting only specific bacterial molecules. Because the drug is so specific, any mutation in these molecules will interfere with or negate its destructive effect, resulting in antibiotic resistance. Known as Drug delivery Conditions treated with combination therapy include tuberculosis, leprosy, cancer, malaria, and HIV/AIDS. One major benefit of combination therapies is that they reduce development of drug resistance, since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. Artemisinin-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment. Drug Induced Blood Disorders causes of sickle cell anemia,pale skin non steroids anti inflammatory drugs which causes ulcers Using drug repositioning, pharmaceutical companies have achieved a number successes, for example Pfizer's Viagra in erectile dysfunction and Celgene's thalidomide in severe erythema nodosum leprosum. Smaller companies, including Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and SOM Biotech are also performing drug repositioning on a systematic basis. These companies use a combination of approaches including in silico biology and in vivo/in vitro experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.
- Drug Resistance Control
- Drug Development for Multiple Simultaneous Diseases
- Approval Probabilities and Regulatory Review Patterns in Hematological Drugs
- Drug Induced Blood Disorders
- Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Blood Disorders
- Drug Repurposing
Related Conference of New Drug Development in Haematology
New Drug Development in Haematology Conference Speakers
Recommended Sessions
- Blood Disorders and Blood Oncology
- Blood Transplantation, Thrombosis and Hemostasis
- Blood- Components and Functions
- Diagnosis, Treatment and Management of Blood Disorders
- Effect of Advanced Technologies on Blood Based Products
- Hemato-immunology & Stem Cell Research
- Hematologic Malignancies
- Lymph and Associated Diseases
- New Drug Development in Haematology
- Transfusion Medicine and Haematology Research
- Tropical Blood Disorders
- Various Aspects of Haematology
Related Journals
Are you interested in
- Biomarkers in Hematology and Oncology - Hematology Congress 2026 (Germany)
- Blood Disorders: Diagnosis and Treatment - Hematology Congress 2026 (Germany)
- Cancer Genomics & Metabolomics - Hematology Congress 2026 (Germany)
- Case Reports in Hematology - Hematology Congress 2026 (Germany)
- Clinical Haematology - Hematology Congress 2026 (Germany)
- Cord Blood Transplantation - Hematology Congress 2026 (Germany)
- Digital Imaging in Hematology - Hematology Congress 2026 (Germany)
- Haematology and Pharma Industry - Hematology Congress 2026 (Germany)
- Hematologic Cancers - Hematology Congress 2026 (Germany)
- Hematology and Cardio-Oncology - Hematology Congress 2026 (Germany)
- Hematology Nursing - Hematology Congress 2026 (Germany)
- Hematology: Diagnostics and Screening - Hematology Congress 2026 (Germany)
- Hematopoietic Malignancies - Hematology Congress 2026 (Germany)
- Immunohematology - Hematology Congress 2026 (Germany)
- Neuro-Hematology - Hematology Congress 2026 (Germany)
- Organ Specific Cancer - Hematology Congress 2026 (Germany)
- Pediatric Hematology - Hematology Congress 2026 (Germany)
- Stem Cell Therapy - Hematology Congress 2026 (Germany)
- Transfusion Medicines - Hematology Congress 2026 (Germany)
- Vascular Bleeding Disorders - Hematology Congress 2026 (Germany)
